Combination therapy studies with L-asparaginase (NSC-109229) and other antitumor agents.
D000081:Acetamides / Q000627:therapeutic use; D000596:Amino Acids / Q000627:therapeutic use; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D001377:Azaserine / Q000627:therapeutic use; D001391:Azo Compounds / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D007942:Leukemia, Experimental / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D051379:Mice; D009368:Neoplasm Transplantation; D011241:Prednisone / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012266:Ribose / Q000627:therapeutic use
D000081:Acetamides; D000596:Amino Acids; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D001391:Azo Compounds; D011758:Pyrroles; D003609:Dactinomycin; D012266:Ribose; D001377:Azaserine; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone